` DXB (Dimerix Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

DXB
vs
S
S&P/ASX 300

Over the past 12 months, DXB has outperformed S&P/ASX 300, delivering a return of +16% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
DXB vs S&P/ASX 300

Loading
DXB
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
DXB vs S&P/ASX 300

Performance Gap Between DXB and AXKO
HIDDEN
Show

Performance By Year
DXB vs S&P/ASX 300

Loading
DXB
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Dimerix Ltd vs Peers

S&P/ASX 300
DXB
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Dimerix Ltd
Glance View

Market Cap
332.2m AUD
Industry
Biotechnology

Dimerix Ltd. engages in the investment in research and development of biopharmaceutical drugs. The company is headquartered in Melbourne, Victoria. The firm is engaged in the development of new therapies in areas with unmet medical need. The firm is developing four product indications: Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19, diabetic kidney disease, and DMX-700 for Chronic Obstructive Pulmonary Disease (COPD), as well as the its Receptor-HIT assay technology. The Company’s pipeline products include DMX-200, DMX-700 and DMX-XXX. DMX-200, which is developed for FSGS, COVID-19 pneumonia patient in ICU and respiratory complications in COVID-19 patients is under Phase III clinical trial. DMX-200, which is developed for diabetic kidney disease is under Phase II clinical trial. DMX-700, which is developed for COPD is under Phase I clinical trial. DMX-XXX is under Phase I clinical trial.

DXB Intrinsic Value
HIDDEN
Show
Back to Top